Danish Business Authority's decision causes Lundbeck to downgrade guidance

Lundbeck adjusts its EBIT guidance after the Danish Business Authority ordered a reassessment of the impairment.

Photo: Martin Lehmann/Ritzau Scanpix

Now, the Danish pharmaceutical firm Lundbeck's operational guidance for 2020 is at DKK 1.7-1.9bn (USD 275.6m-308.0m), down from DKK 2.0-2.2n. Lundbeck, however, states that its guidance for earnings before interest, taxes, depreciations and amortizations and core EBIT remain unchanged, according to a stock exchange announcement on Friday afternoon.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs